Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR-C4: Elbasvir/Grazoprevir in Egyptian Patients With ESRD and HCV GT4
NCT03381859Phase 4Withdrawn
- Sponsor
- University of Maryland, Baltimore
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of elbasvir and grazoprevir in hepatitis C (HCV), sponsored by University of Maryland, Baltimore. Primary endpoint: Sustained Viral Response at 12 Weeks Post-Treatment. Planned start Dec 2019; status: withdrawn.
02
Drugs
elbasvirgrazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03381859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381859.